Jim Kastenmayer, JD, PhD, will step down as interim CEO and retain his position as Aeglea’s general counsel. "On behalf of the entire board of directors, I want to thank Jim for his service and commitment to Aeglea and its mission. Jim has provided exceptional leadership during a period of critical execution and has kept the team focused on advancing the Homocystinuria program," said the company.
Published first on TheFly
Read More on AGLE: